Skip to main content

In HF with LVEF ≤ 42.5%, sacubitril-valsartan vs RAS inhibitors reduced a composite of CV death or HF hospitalization.

Publication ,  Journal Article
Sen, S; Newby, LK
Published in: Ann Intern Med
June 16, 2020

Solomon SD, Vaduganathan M, Claggett BL, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020;141:352-61. 31736342.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

June 16, 2020

Volume

172

Issue

12

Start / End Page

JC65

Location

United States

Related Subject Headings

  • Valsartan
  • Tetrazoles
  • Stroke Volume
  • Humans
  • Hospitalization
  • Heart Failure
  • General & Internal Medicine
  • Drug Combinations
  • Biphenyl Compounds
  • Angiotensin Receptor Antagonists
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sen, S., & Newby, L. K. (2020). In HF with LVEF ≤ 42.5%, sacubitril-valsartan vs RAS inhibitors reduced a composite of CV death or HF hospitalization. Ann Intern Med, 172(12), JC65. https://doi.org/10.7326/ACPJ202006160-065
Sen, Sounok, and L Kristin Newby. “In HF with LVEF ≤ 42.5%, sacubitril-valsartan vs RAS inhibitors reduced a composite of CV death or HF hospitalization.Ann Intern Med 172, no. 12 (June 16, 2020): JC65. https://doi.org/10.7326/ACPJ202006160-065.
Sen, Sounok, and L. Kristin Newby. “In HF with LVEF ≤ 42.5%, sacubitril-valsartan vs RAS inhibitors reduced a composite of CV death or HF hospitalization.Ann Intern Med, vol. 172, no. 12, June 2020, p. JC65. Pubmed, doi:10.7326/ACPJ202006160-065.

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

June 16, 2020

Volume

172

Issue

12

Start / End Page

JC65

Location

United States

Related Subject Headings

  • Valsartan
  • Tetrazoles
  • Stroke Volume
  • Humans
  • Hospitalization
  • Heart Failure
  • General & Internal Medicine
  • Drug Combinations
  • Biphenyl Compounds
  • Angiotensin Receptor Antagonists